社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Carolinetsh
IP属地：未知
+关注
帖子 · 95
帖子 · 95
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Carolinetsh
Carolinetsh
·
2021-11-13
Just sold mine
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
看
3,393
回复
2
点赞
6
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-11
$Pfizer(PFE)$
Up up up
看
3,821
回复
评论
点赞
2
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-09
$Apple(AAPL)$
Drop again
看
2,237
回复
评论
点赞
3
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-08
$Alibaba(BABA)$
When will it goes up to $200?
看
3,551
回复
评论
点赞
1
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-07
Pfizer is the way to go
非常抱歉，此主贴已删除
看
3,323
回复
1
点赞
2
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-06
Up up up
非常抱歉，此主贴已删除
看
3,661
回复
评论
点赞
2
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-04
Please go up up up
EV stocks climbed in morning trading<blockquote>电动汽车股早盘上涨</blockquote>
EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola and Lordstown rose between 1% and 4%.
EV stocks climbed in morning trading<blockquote>电动汽车股早盘上涨</blockquote>
看
4,245
回复
1
点赞
5
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-04
Dun drop please
Hot chinese concept stocks rallied in premarket trading<blockquote>热门中概股盘前上涨</blockquote>
Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE h
Hot chinese concept stocks rallied in premarket trading<blockquote>热门中概股盘前上涨</blockquote>
看
2,698
回复
1
点赞
8
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-11-03
Good
Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>
Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales Of t
Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>
看
3,635
回复
1
点赞
1
编组 21备份 2
分享
举报
Carolinetsh
Carolinetsh
·
2021-10-27
$Alibaba(BABA)$
What happens again?
看
2,104
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582507638581570","uuid":"3582507638581570","gmtCreate":1619499677057,"gmtModify":1619499677057,"name":"Carolinetsh","pinyin":"carolinetsh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":31,"headSize":376,"tweetSize":95,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":873062154,"gmtCreate":1636803354904,"gmtModify":1636803355129,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Just sold mine ","listText":"Just sold mine ","text":"Just sold mine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873062154","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870638605,"gmtCreate":1636608708026,"gmtModify":1636608708239,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Up up up","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Up up up","text":"$Pfizer(PFE)$Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870638605","isVote":1,"tweetType":1,"viewCount":3821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844729171,"gmtCreate":1636462121695,"gmtModify":1636462122268,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Drop again ","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Drop again ","text":"$Apple(AAPL)$Drop again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844729171","isVote":1,"tweetType":1,"viewCount":2237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845536378,"gmtCreate":1636349180795,"gmtModify":1636349181234,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>When will it goes up to $200?","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>When will it goes up to $200?","text":"$Alibaba(BABA)$When will it goes up to $200?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845536378","isVote":1,"tweetType":1,"viewCount":3551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845983675,"gmtCreate":1636264427454,"gmtModify":1636264478168,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Pfizer is the way to go","listText":"Pfizer is the way to go","text":"Pfizer is the way to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845983675","repostId":"2181742241","repostType":4,"isVote":1,"tweetType":1,"viewCount":3323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842277559,"gmtCreate":1636192322891,"gmtModify":1636192323359,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Up up up","listText":"Up up up","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842277559","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":3661,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846098273,"gmtCreate":1636033996643,"gmtModify":1636034004896,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please go up up up","listText":"Please go up up up","text":"Please go up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846098273","repostId":"1107936396","repostType":4,"repost":{"id":"1107936396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636033656,"share":"https://www.laohu8.com/m/news/1107936396?lang=zh_CN&edition=full","pubTime":"2021-11-04 21:47","market":"us","language":"en","title":"EV stocks climbed in morning trading<blockquote>电动汽车股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107936396","media":"Tiger Newspress","summary":"EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola and Lordstown rose between 1% and 4%.","content":"<p>EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola and Lordstown rose between 1% and 4%.</p><p><blockquote>电动汽车股早盘上涨。特斯拉、蔚来、小鹏汽车、理想汽车、尼古拉和洛兹敦涨幅在1%至4%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e14b7478da56a6589e4e564ba13f7bbc\" tg-width=\"402\" tg-height=\"475\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks climbed in morning trading<blockquote>电动汽车股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks climbed in morning trading<blockquote>电动汽车股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 21:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola and Lordstown rose between 1% and 4%.</p><p><blockquote>电动汽车股早盘上涨。特斯拉、蔚来、小鹏汽车、理想汽车、尼古拉和洛兹敦涨幅在1%至4%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e14b7478da56a6589e4e564ba13f7bbc\" tg-width=\"402\" tg-height=\"475\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","LI":"理想汽车","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107936396","content_text":"EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola and Lordstown rose between 1% and 4%.","news_type":1,"symbols_score_info":{"TSLA":0.9,"XPEV":0.9,"LI":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":4245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848406158,"gmtCreate":1636016403992,"gmtModify":1636016404375,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Dun drop please","listText":"Dun drop please","text":"Dun drop please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848406158","repostId":"1167064150","repostType":4,"repost":{"id":"1167064150","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636015649,"share":"https://www.laohu8.com/m/news/1167064150?lang=zh_CN&edition=full","pubTime":"2021-11-04 16:47","market":"us","language":"en","title":"Hot chinese concept stocks rallied in premarket trading<blockquote>热门中概股盘前上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167064150","media":"Tiger Newspress","summary":"Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE h","content":"<p>Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE holding,Didi Global,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.</p><p><blockquote>热门中概股盘前上涨，阿里巴巴-SW、京东、拼多多、百度、哔哩哔哩、贝壳控股、滴滴全球、蔚来、小鹏汽车和理想汽车涨幅在1%至4%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/62b8b12c5eeaa21666c060337f5740ff\" tg-width=\"403\" tg-height=\"718\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot chinese concept stocks rallied in premarket trading<blockquote>热门中概股盘前上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot chinese concept stocks rallied in premarket trading<blockquote>热门中概股盘前上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 16:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE holding,Didi Global,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.</p><p><blockquote>热门中概股盘前上涨，阿里巴巴-SW、京东、拼多多、百度、哔哩哔哩、贝壳控股、滴滴全球、蔚来、小鹏汽车和理想汽车涨幅在1%至4%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/62b8b12c5eeaa21666c060337f5740ff\" tg-width=\"403\" tg-height=\"718\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","JD":"京东","PDD":"拼多多"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167064150","content_text":"Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE holding,Didi Global,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.","news_type":1,"symbols_score_info":{"BABA":0.9,"PDD":0.9,"JD":0.9}},"isVote":1,"tweetType":1,"viewCount":2698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841587163,"gmtCreate":1635926115553,"gmtModify":1635926115709,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841587163","repostId":"1167449573","repostType":4,"repost":{"id":"1167449573","kind":"news","pubTimestamp":1635922924,"share":"https://www.laohu8.com/m/news/1167449573?lang=zh_CN&edition=full","pubTime":"2021-11-03 15:02","market":"us","language":"en","title":"Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167449573","media":"The Wall Street Journal","summary":"Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf t","content":"<p>Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales</p><p><blockquote>Shot 130亿美元的收入为制药商第三季度销售额做出了最大贡献</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/85ed5523396f63a03a4597730fa17ed8\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>Of the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.</span></p><p><blockquote><p class=\"t-img-caption\"><span>在近2亿已完全接种疫苗的美国人中，超过一半的人接种了辉瑞疫苗。</span></p></blockquote></p><p> Pfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.</p><p><blockquote>辉瑞公司(Pfizer Inc.)将今年Covid-19疫苗的销售额预测上调至约360亿美元，增幅约7%，正值美国准备向2800万5至11岁儿童分发疫苗之际。</blockquote></p><p> The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.</p><p><blockquote>这家总部位于纽约的制药商表示，其与合作伙伴BioNTech SE开发的疫苗的销售预测考虑了今年预计交付约23亿剂疫苗。这些公司已经提高了生产剂量的能力，并正在与海外其他公司合作生产剂量。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。辉瑞首席执行官Albert Bourla在财报看涨期权上表示，今年超过75%的疫苗销售额来自国际销售，因为该疫苗已到达152个国家。</blockquote></p><p> The vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.</p><p><blockquote>在接受初始供应的国家和其他已经开始加强运动的国家，以及尚未接受任何供应的国家，该疫苗在全球范围内仍然有需求。美国已授权为许多高危成年人额外注射该疫苗，并于上周批准将该疫苗用于5岁以下的儿童。</blockquote></p><p> In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.</p><p><blockquote>在美国，该疫苗预计最早将于周三在一些地方提供给幼儿，因为疾病控制和预防中心周二晚上批准在儿童中使用该疫苗。在美国食品和药物管理局上周授权在临床试验之外使用疫苗后，该机构的认可是疫苗接种前的最后一步。9月份，许多高危成年人获得了疫苗加强注射的许可。</blockquote></p><p> Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.</p><p><blockquote>辉瑞计划明年生产约40亿剂，但已获得17亿剂的订单。布尔拉在接受采访时表示，订单数量表明它正在满足需求，低收入国家应该先于富裕国家达成供应协议，以避免像世界上最初推出疫苗那样落后。</blockquote></p><p> “We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”</p><p><blockquote>“根据我们现有的订单，我们的需求已经远远超出了我们的预测，”布尔拉先生说。“如果有订单，我们明年会生产更多。”</blockquote></p><p> While data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，虽然辉瑞和其他研究人员的数据显示，额外剂量可能会增加保护作用，但研究第四剂疫苗的试验可能会在明年春天开始，大约在其研究中的试验对象接受第三剂疫苗一年后。在一次采访中。</blockquote></p><p> That could lead to study results in time for people to get a fourth dose when they get flu shots.</p><p><blockquote>这可能会让人们在注射流感疫苗时及时获得第四剂疫苗的研究结果。</blockquote></p><p> “It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.</p><p><blockquote>他说：“这实际上是为了为我们认为很可能需要每年重新接种疫苗的情况做好准备。”</blockquote></p><p> The company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.</p><p><blockquote>该公司最近表示，在一项大型研究中发现，第三剂疫苗是安全的，对有症状的Covid-19具有高度保护作用。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。Bourla先生说，今年超过75%的疫苗销售额来自国际销售，因为疫苗已经到达152个国家。</blockquote></p><p> Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.</p><p><blockquote>辉瑞表示，预计其实验性Covid-19抗病毒药物的初步结果将于2022年第一季度末公布，该药物正处于后期测试阶段。研究人员正在接种疫苗和未接种疫苗的人以及低风险个体中研究该药物，这可能会将其与美国食品和药物管理局正在审查的默克公司和Ridgeback Biotherapeutics LP的一种有前途的抗病毒药物区分开来。</blockquote></p><p> The company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.</p><p><blockquote>该公司已开始向FDA提供科学数据，尽管尚未正式请求授权。布尔拉说，如果获得授权，辉瑞公司今年将能够交付疫苗。</blockquote></p><p> Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.</p><p><blockquote>辉瑞生物制药总裁Angela Hwang表示，辉瑞预计全球多达1.5亿成年人可能因感染和密切接触而需要抗病毒药物。她说，长期销售和政府储存合同都有潜力。</blockquote></p><p> Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.</p><p><blockquote>辉瑞预测，明年17亿剂的销售额将达到290亿美元，这反映了长期销售的持久性以及各国在冬季遏制病毒传播的努力。布尔拉先生说，许多国家将购买儿科剂量。明年的收入可能会更高，因为该预测反映了截至10月中旬签署的供应协议。</blockquote></p><p></p><p> Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.</p><p><blockquote>如果销售实现，他们将使辉瑞-BioNTech疫苗成为有史以来最畅销的药品。近年来全球最畅销的处方药是艾伯维公司（AbbVie Inc.）的抗炎药修美乐（Humira），2018年销售额近200亿美元。</blockquote></p><p> Pfizer splits vaccine sales with BioNTech.</p><p><blockquote>辉瑞与BioNTech分享疫苗销售。</blockquote></p><p> The outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.</p><p><blockquote>辉瑞疫苗的前景反映了该疫苗相对于竞争对手疫苗的偏好。近2亿美国人已完全接种疫苗，其中一半以上接种了辉瑞-BioNTech疫苗。其余的大多数人接受了Moderna Inc.的疫苗，该疫苗使用类似的基于mRNA的技术。</blockquote></p><p> Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.</p><p><blockquote>到目前为止，辉瑞公司也已经分发了20亿剂，并有望生产30亿剂。</blockquote></p><p> Mr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.</p><p><blockquote>布尔拉在采访中敦促贫穷国家确保明年的供应——以折扣或非盈利价格——他希望避免重蹈又一年落后于富裕国家的覆辙。他表示，希望世界卫生组织和Covax能够提供帮助。</blockquote></p><p> The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.</p><p><blockquote>Covax计划由包括联合国儿童基金会和世卫组织在内的许多组织管理，旨在为富国和穷国提供公平获得疫苗的机会。</blockquote></p><p> Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.</p><p><blockquote>布尔拉表示，他已经致函各国，要求它们下订单，并表示它们应该比过去更加积极主动。</blockquote></p><p> “Some governments are better than others,” he said. “That’s the problem.”</p><p><blockquote>“有些政府比其他政府更好，”他说。“这就是问题所在。”</blockquote></p><p> Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.</p><p><blockquote>辉瑞和其他疫苗制造商因没有向中低收入国家提供足够的剂量而面临各国、公共卫生官员和药品获取倡导者的批评。一些国家缺乏与公司达成交易的资金或自行注射疫苗的知识，迫使它们依赖Covax计划。有供应协议的国家也因冷藏疫苗所需的基础设施不足而受到阻碍。</blockquote></p><p> Only 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.</p><p><blockquote>根据我们的世界数据，低收入国家只有3.7%的人至少接种了一剂Covid-19疫苗。一些批评者提议政府放弃知识产权以刺激生产，但这一想法遭到了疫苗制造商的拒绝。</blockquote></p><p> The Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.</p><p><blockquote>辉瑞-BioNTech疫苗预计很快将在美国提供给5岁以下的儿童，此前美国卫生当局上周授权其紧急使用，作为青少年的第一针Covid-19疫苗。该疫苗完全被批准用于16岁及以上的人，并被批准用于12岁及以上的儿童紧急使用。</blockquote></p><p> U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.</p><p><blockquote>美国监管机构已批准为接种辉瑞-BioNTech疫苗的人在接种第二剂疫苗后至少六个月内接种加强剂，只要他们是老年人或因潜在疾病或工作场所而处于高风险。此后，监管机构将加强剂的可用性扩大到接受Moderna或强生的人。</blockquote></p><p> The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.</p><p><blockquote>辉瑞-BioNTech疫苗通过临床试验和监管障碍的进展速度快于竞争对手批准用于成人的疫苗。</blockquote></p><p> Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.</p><p><blockquote>Dolsten博士说，辉瑞-BioNTech疫苗在2至4岁儿童中的临床研究的初步结果预计将于今年年底公布，而6个月至2岁以下儿童的数据将于下一季度末公布。</blockquote></p><p> Moderna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.</p><p><blockquote>Moderna最近表示，在FDA批准青少年接种疫苗之前，它不会寻求批准其疫苗用于幼儿。强生公司是第三种获准在美国使用的疫苗，正在研究青少年的注射，但尚未开始在更小的儿童中研究。</blockquote></p><p> Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.</p><p><blockquote>辉瑞还上调了今年的整体财务指引，预计销售额为810亿美元至820亿美元，调整后每股收益为4.13美元至4.18美元。它将这一增长归因于疫苗和非疫苗的势头。</blockquote></p><p> Excluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.</p><p><blockquote>不包括Covid-19疫苗，辉瑞其他药物的销售额增长了7%。由于乳腺癌治疗药物Ibrance和前列腺癌药物Xtandi的销售额猛增，肿瘤药物销售额增长12%，达到超过30亿美元。血液稀释剂收入增长21%，超过13亿美元。</blockquote></p><p> Stripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.</p><p><blockquote>剔除一次性项目，该公司第三季度调整后利润为每股1.34美元。华尔街分析师此前预测营收为225.8亿美元，调整后每股收益为1.08美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double<blockquote>辉瑞上调Covid-19疫苗预测，销售额增加一倍多</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-03 15:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales</p><p><blockquote>Shot 130亿美元的收入为制药商第三季度销售额做出了最大贡献</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/85ed5523396f63a03a4597730fa17ed8\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>Of the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.</span></p><p><blockquote><p class=\"t-img-caption\"><span>在近2亿已完全接种疫苗的美国人中，超过一半的人接种了辉瑞疫苗。</span></p></blockquote></p><p> Pfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.</p><p><blockquote>辉瑞公司(Pfizer Inc.)将今年Covid-19疫苗的销售额预测上调至约360亿美元，增幅约7%，正值美国准备向2800万5至11岁儿童分发疫苗之际。</blockquote></p><p> The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.</p><p><blockquote>这家总部位于纽约的制药商表示，其与合作伙伴BioNTech SE开发的疫苗的销售预测考虑了今年预计交付约23亿剂疫苗。这些公司已经提高了生产剂量的能力，并正在与海外其他公司合作生产剂量。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。辉瑞首席执行官Albert Bourla在财报看涨期权上表示，今年超过75%的疫苗销售额来自国际销售，因为该疫苗已到达152个国家。</blockquote></p><p> The vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.</p><p><blockquote>在接受初始供应的国家和其他已经开始加强运动的国家，以及尚未接受任何供应的国家，该疫苗在全球范围内仍然有需求。美国已授权为许多高危成年人额外注射该疫苗，并于上周批准将该疫苗用于5岁以下的儿童。</blockquote></p><p> In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.</p><p><blockquote>在美国，该疫苗预计最早将于周三在一些地方提供给幼儿，因为疾病控制和预防中心周二晚上批准在儿童中使用该疫苗。在美国食品和药物管理局上周授权在临床试验之外使用疫苗后，该机构的认可是疫苗接种前的最后一步。9月份，许多高危成年人获得了疫苗加强注射的许可。</blockquote></p><p> Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.</p><p><blockquote>辉瑞计划明年生产约40亿剂，但已获得17亿剂的订单。布尔拉在接受采访时表示，订单数量表明它正在满足需求，低收入国家应该先于富裕国家达成供应协议，以避免像世界上最初推出疫苗那样落后。</blockquote></p><p> “We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”</p><p><blockquote>“根据我们现有的订单，我们的需求已经远远超出了我们的预测，”布尔拉先生说。“如果有订单，我们明年会生产更多。”</blockquote></p><p> While data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)表示，虽然辉瑞和其他研究人员的数据显示，额外剂量可能会增加保护作用，但研究第四剂疫苗的试验可能会在明年春天开始，大约在其研究中的试验对象接受第三剂疫苗一年后。在一次采访中。</blockquote></p><p> That could lead to study results in time for people to get a fourth dose when they get flu shots.</p><p><blockquote>这可能会让人们在注射流感疫苗时及时获得第四剂疫苗的研究结果。</blockquote></p><p> “It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.</p><p><blockquote>他说：“这实际上是为了为我们认为很可能需要每年重新接种疫苗的情况做好准备。”</blockquote></p><p> The company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.</p><p><blockquote>该公司最近表示，在一项大型研究中发现，第三剂疫苗是安全的，对有症状的Covid-19具有高度保护作用。</blockquote></p><p> The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.</p><p><blockquote>该疫苗130亿美元的收入是辉瑞第三季度约240亿美元销售额的最大贡献者，同比增长了一倍多。Bourla先生说，今年超过75%的疫苗销售额来自国际销售，因为疫苗已经到达152个国家。</blockquote></p><p> Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.</p><p><blockquote>辉瑞表示，预计其实验性Covid-19抗病毒药物的初步结果将于2022年第一季度末公布，该药物正处于后期测试阶段。研究人员正在接种疫苗和未接种疫苗的人以及低风险个体中研究该药物，这可能会将其与美国食品和药物管理局正在审查的默克公司和Ridgeback Biotherapeutics LP的一种有前途的抗病毒药物区分开来。</blockquote></p><p> The company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.</p><p><blockquote>该公司已开始向FDA提供科学数据，尽管尚未正式请求授权。布尔拉说，如果获得授权，辉瑞公司今年将能够交付疫苗。</blockquote></p><p> Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.</p><p><blockquote>辉瑞生物制药总裁Angela Hwang表示，辉瑞预计全球多达1.5亿成年人可能因感染和密切接触而需要抗病毒药物。她说，长期销售和政府储存合同都有潜力。</blockquote></p><p> Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.</p><p><blockquote>辉瑞预测，明年17亿剂的销售额将达到290亿美元，这反映了长期销售的持久性以及各国在冬季遏制病毒传播的努力。布尔拉先生说，许多国家将购买儿科剂量。明年的收入可能会更高，因为该预测反映了截至10月中旬签署的供应协议。</blockquote></p><p></p><p> Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.</p><p><blockquote>如果销售实现，他们将使辉瑞-BioNTech疫苗成为有史以来最畅销的药品。近年来全球最畅销的处方药是艾伯维公司（AbbVie Inc.）的抗炎药修美乐（Humira），2018年销售额近200亿美元。</blockquote></p><p> Pfizer splits vaccine sales with BioNTech.</p><p><blockquote>辉瑞与BioNTech分享疫苗销售。</blockquote></p><p> The outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.</p><p><blockquote>辉瑞疫苗的前景反映了该疫苗相对于竞争对手疫苗的偏好。近2亿美国人已完全接种疫苗，其中一半以上接种了辉瑞-BioNTech疫苗。其余的大多数人接受了Moderna Inc.的疫苗，该疫苗使用类似的基于mRNA的技术。</blockquote></p><p> Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.</p><p><blockquote>到目前为止，辉瑞公司也已经分发了20亿剂，并有望生产30亿剂。</blockquote></p><p> Mr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.</p><p><blockquote>布尔拉在采访中敦促贫穷国家确保明年的供应——以折扣或非盈利价格——他希望避免重蹈又一年落后于富裕国家的覆辙。他表示，希望世界卫生组织和Covax能够提供帮助。</blockquote></p><p> The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.</p><p><blockquote>Covax计划由包括联合国儿童基金会和世卫组织在内的许多组织管理，旨在为富国和穷国提供公平获得疫苗的机会。</blockquote></p><p> Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.</p><p><blockquote>布尔拉表示，他已经致函各国，要求它们下订单，并表示它们应该比过去更加积极主动。</blockquote></p><p> “Some governments are better than others,” he said. “That’s the problem.”</p><p><blockquote>“有些政府比其他政府更好，”他说。“这就是问题所在。”</blockquote></p><p> Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.</p><p><blockquote>辉瑞和其他疫苗制造商因没有向中低收入国家提供足够的剂量而面临各国、公共卫生官员和药品获取倡导者的批评。一些国家缺乏与公司达成交易的资金或自行注射疫苗的知识，迫使它们依赖Covax计划。有供应协议的国家也因冷藏疫苗所需的基础设施不足而受到阻碍。</blockquote></p><p> Only 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.</p><p><blockquote>根据我们的世界数据，低收入国家只有3.7%的人至少接种了一剂Covid-19疫苗。一些批评者提议政府放弃知识产权以刺激生产，但这一想法遭到了疫苗制造商的拒绝。</blockquote></p><p> The Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.</p><p><blockquote>辉瑞-BioNTech疫苗预计很快将在美国提供给5岁以下的儿童，此前美国卫生当局上周授权其紧急使用，作为青少年的第一针Covid-19疫苗。该疫苗完全被批准用于16岁及以上的人，并被批准用于12岁及以上的儿童紧急使用。</blockquote></p><p> U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.</p><p><blockquote>美国监管机构已批准为接种辉瑞-BioNTech疫苗的人在接种第二剂疫苗后至少六个月内接种加强剂，只要他们是老年人或因潜在疾病或工作场所而处于高风险。此后，监管机构将加强剂的可用性扩大到接受Moderna或强生的人。</blockquote></p><p> The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.</p><p><blockquote>辉瑞-BioNTech疫苗通过临床试验和监管障碍的进展速度快于竞争对手批准用于成人的疫苗。</blockquote></p><p> Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.</p><p><blockquote>Dolsten博士说，辉瑞-BioNTech疫苗在2至4岁儿童中的临床研究的初步结果预计将于今年年底公布，而6个月至2岁以下儿童的数据将于下一季度末公布。</blockquote></p><p> Moderna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.</p><p><blockquote>Moderna最近表示，在FDA批准青少年接种疫苗之前，它不会寻求批准其疫苗用于幼儿。强生公司是第三种获准在美国使用的疫苗，正在研究青少年的注射，但尚未开始在更小的儿童中研究。</blockquote></p><p> Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.</p><p><blockquote>辉瑞还上调了今年的整体财务指引，预计销售额为810亿美元至820亿美元，调整后每股收益为4.13美元至4.18美元。它将这一增长归因于疫苗和非疫苗的势头。</blockquote></p><p> Excluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.</p><p><blockquote>不包括Covid-19疫苗，辉瑞其他药物的销售额增长了7%。由于乳腺癌治疗药物Ibrance和前列腺癌药物Xtandi的销售额猛增，肿瘤药物销售额增长12%，达到超过30亿美元。血液稀释剂收入增长21%，超过13亿美元。</blockquote></p><p> Stripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.</p><p><blockquote>剔除一次性项目，该公司第三季度调整后利润为每股1.34美元。华尔街分析师此前预测营收为225.8亿美元，调整后每股收益为1.08美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167449573","content_text":"Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.\nPfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.\nThe New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.\nThe vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.\nThe vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.\nIn the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.\nPfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.\n“We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”\nWhile data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.\nThat could lead to study results in time for people to get a fourth dose when they get flu shots.\n“It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.\nThe company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.\nThe vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.\nPfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.\nThe company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.\nPfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.\nPfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.\nShould the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.\nPfizer splits vaccine sales with BioNTech.\nThe outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.\nPfizer has also distributed two billion doses so far and is on track to produce three billion doses.\nMr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.\nThe Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.\nMr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.\n“Some governments are better than others,” he said. “That’s the problem.”\nPfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.\nOnly 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.\nThe Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.\nU.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.\nThe Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.\nInitial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.\nModerna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.\nPfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.\nExcluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.\nStripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852552146,"gmtCreate":1635293000201,"gmtModify":1635293070740,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>What happens again?","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>What happens again?","text":"$Alibaba(BABA)$What happens again?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852552146","isVote":1,"tweetType":1,"viewCount":2104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}